Adductor Canal Block With Dexamethasone Versus Adductor Canal Block With Systemic Dexamethasone in Arthroscopic Anterior Cruciate Ligament Repair
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Benha University
- Enrollment
- 123
- Locations
- 1
- Primary Endpoint
- Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-arthroscopic ACL management.
Study Overview
Brief Summary
Arthroscopic knee injuries, such as the anterior cruciate ligament (ACL) injury, are common and often result in postoperative pain. Regional anesthetic techniques, such as femoral nerve block (FNB) and adductor canal block (ACB), can help alleviate pain and reduce opioid consumption. ACB, which blocks the saphenous nerve and obturator nerve branches, is preferred over FNB due to its potential to decrease mobility and increase falls risk. Dexamethasone, a potent glucocorticoid, is used as an adjuvant for ACB, but its perineural administration may carry neurotoxicity risks. Some pain physicians prefer intravenous administration to prolong the action of local anesthetics used in peripheral nerve blocks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients diagnosed with ACL injury;
- •Patients in class I, II according to American Society of Anesthesiologists (ASA) classification.
Exclusion Criteria
- •Patients free of all Inclusion Criteria.
Arms & Interventions
IV anesthetic Group
Intervention: Dexamethasone injection (Drug)
IV anesthetic Group
Intervention: Bupivacaine 0.375% Injectable Solution (Drug)
Local anesthetic Group
Intervention: Dexamethasone injection (Drug)
Local anesthetic Group
Intervention: Bupivacaine 0.5% Injectable Solution (Drug)
Control Group
Intervention: Bupivacaine 0.375% Injectable Solution (Drug)
Outcomes
Primary Outcomes
Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-arthroscopic ACL management.
Time Frame: 6 months
Value of administration of dexamethasone enhancing the analgesic action of bupivacaine used in ACB after arthroscopic management of the ACL.
Secondary Outcomes
No secondary outcomes reported
Investigators
Mahmoud Sharara
Lecturer of Anesthesiology, Pain, and ICU Department
Benha University